All > Bc Prostate Cancer > Honolulu

Pembrolizumab for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Northeast Georgia Medical Center Braselton, Braselton, GANon-Small Cell Lung Cancer+5 MorePembrolizumab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with advanced non-squamous non-small cell lung cancer.

Eligible Conditions
  • Non-squamous Non-small-cell Lung Cancer
  • Stage IVB Lung Cancer
  • Stage III Lung Cancer
  • Stage IIIB Lung Cancer
  • Stage IV Lung Cancer
  • Stage IVA Lung Cancer

Video Summary

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Pemetrexed (Chemotherapy)
1
Binimetinib
1
Stereotactic Body Radiation Therapy

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Up to 5 years post treatment

At baseline
PD-L1 positivity
Year 5
Overall survival (OS)
Year 5
Progression-free survival (PFS)
Day 30
Incidence of adverse events
Year 5
Best objective response

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Pemetrexed (Chemotherapy)
1
Binimetinib
2
Stereotactic Body Radiation Therapy

Trial Design

3 Treatment Groups

Arm C (pembrolizumab, pembrolizumab, carboplatin)
1 of 3
Arm A (pembrolizumab, pemetrexed, carboplatin)
1 of 3
Arm B (pembrolizumab, pemetrexed, carboplatin)
1 of 3

Active Control

Experimental Treatment

846 Total Participants · 3 Treatment Groups

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 3

Arm A (pembrolizumab, pemetrexed, carboplatin)Experimental Group · 3 Interventions: Carboplatin, Pembrolizumab, Pemetrexed · Intervention Types: Drug, Biological, Drug
Arm B (pembrolizumab, pemetrexed, carboplatin)Experimental Group · 3 Interventions: Carboplatin, Pembrolizumab, Pemetrexed · Intervention Types: Drug, Biological, Drug
Arm C (pembrolizumab, pembrolizumab, carboplatin)ActiveComparator Group · 3 Interventions: Carboplatin, Pembrolizumab, Pemetrexed · Intervention Types: Drug, Biological, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
FDA approved
Pembrolizumab
FDA approved
Pemetrexed
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years post treatment

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,163 Previous Clinical Trials
41,166,419 Total Patients Enrolled
Hossein BorghaeiPrincipal InvestigatorECOG-ACRIN Cancer Research Group
2 Previous Clinical Trials
42 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 25 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Rewritten Criterion: If you are given the drug pemetrexed, your healthcare provider will follow specific guidelines for draining fluids from your body.
Rewritten Criterion: You can continue to take your medication for seizures.
Rewritten Criterion: You can continue to take your medication for seizures.
Rewritten Criterion: If you are given the drug pemetrexed, your healthcare provider will follow specific guidelines for draining fluids from your body.

Who else is applying?

What state do they live in?
Texas33.3%
Iowa33.3%
California33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
Kaiser Permanente-San Francisco33.3%
Alegent Health Mercy Hospital33.3%
Methodist Willowbrook Hospital33.3%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%
How many prior treatments have patients received?
0100.0%

How responsive is this trial?

Typically responds via
Phone Call100.0%
Most responsive sites:
  1. Alegent Health Mercy Hospital: < 48 hours
Average response time
  • < 2 Days
References

Frequently Asked Questions

What type of illnesses or diseases is Pembrolizumab mostly effective for?

"Pembrolizumab is an immunotherapy medication that can be used to treat various types of cancer, such as malignant neoplasms, unresectable melanoma, and microsatellite instability high." - Anonymous Online Contributor

Unverified Answer

What does the existing literature say about Pembrolizumab?

"Pembrolizumab is being trialed in 1664 different ongoing studies, with 337 of those in Phase 3. Though many of these trials are based in Shanghai, there are 74921 total locations for these trials." - Anonymous Online Contributor

Unverified Answer

What is the general consensus on Pembrolizumab's effectiveness?

"Pembrolizumab has received a safety score of 3. This is because it is a Phase 3 trial, which means that there is not only data supporting its efficacy, but also multiple rounds of data affirming its safety." - Anonymous Online Contributor

Unverified Answer

Are people with this condition still able to enroll in the trial at this time?

"That is correct, according to the information available on clinicaltrials.gov, this clinical trial is still recruiting participants. The study was originally posted on 2/28/2019, and the most recent edit was on 11/3/2022. They are hoping to enroll 846 participants from 100 different locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top